Pacira BioSciences' Non-Current Debt rose 252.00% to $376.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $376.7 million, marking a year-over-year increase of 252.00%. This contributed to the annual value of $383.5 million for FY2024, which is 232.93% up from last year.
Latest data reveals that Pacira BioSciences reported Non-Current Debt of $376.7 million as of Q3 2025, which was up 285.09% from $97.8 million recorded in Q2 2025.
Pacira BioSciences' Non-Current Debt's 5-year high stood at $383.5 million during Q4 2024, with a 5-year trough of $97.8 million in Q2 2025.
For the 3-year period, Pacira BioSciences' Non-Current Debt averaged around $163.1 million, with its median value being $115.2 million (2023).
In the last 5 years, Pacira BioSciences' Non-Current Debt plummeted by 61.93% in 2023 and then spiked by 252.00% in 2025.
Pacira BioSciences' Non-Current Debt (Quarterly) stood at $335.3 million in 2021, then decreased by 25.12% to $251.1 million in 2022, then tumbled by 54.11% to $115.2 million in 2023, then skyrocketed by 232.93% to $383.5 million in 2024, then spiked by 252.00% to $376.7 million in 2025.
Its last three reported values are $376.7 million in Q3 2025, $97.8 million for Q2 2025, and $101.5 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value